135 related articles for article (PubMed ID: 26559096)
1. Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment.
Kalkan R
Crit Rev Eukaryot Gene Expr; 2015; 25(4):363-9. PubMed ID: 26559096
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning.
Kalkan R
Crit Rev Eukaryot Gene Expr; 2015; 25(4):281-5. PubMed ID: 26559087
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma.
Kalkan R
Clin Med Insights Oncol; 2015; 9():95-103. PubMed ID: 26617463
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications.
Yang L; Lin C; Wang L; Guo H; Wang X
Exp Cell Res; 2012 Nov; 318(19):2417-26. PubMed ID: 22906859
[TBL] [Abstract][Full Text] [Related]
5. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation.
Karsy M; Guan J; Jensen R; Huang LE; Colman H
World Neurosurg; 2016 Apr; 88():222-236. PubMed ID: 26724617
[TBL] [Abstract][Full Text] [Related]
7. Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia.
Maugeri G; D'Amico AG; Rasà DM; Saccone S; Federico C; Magro G; Cavallaro S; D'Agata V
Anticancer Agents Med Chem; 2018; 18(10):1432-1439. PubMed ID: 29424319
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling.
Uribe D; Torres Á; Rocha JD; Niechi I; Oyarzún C; Sobrevia L; San Martín R; Quezada C
Mol Aspects Med; 2017 Jun; 55():140-151. PubMed ID: 28223127
[TBL] [Abstract][Full Text] [Related]
9. Oncogenesis recapitulates embryogenesis via the hypoxia pathway: morphoproteomics and biomedical analytics provide proof of concept and therapeutic options.
Brown RE; McGuire MF
Ann Clin Lab Sci; 2012; 42(3):243-57. PubMed ID: 22964612
[TBL] [Abstract][Full Text] [Related]
10. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
12. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.
Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS
Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma cancer stem cell biology: Potential theranostic targets.
Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
[TBL] [Abstract][Full Text] [Related]
14. Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review).
Bryukhovetskiy I; Bryukhovetskiy A; Khotimchenko Y; Mischenko P
Oncol Rep; 2016 Feb; 35(2):639-48. PubMed ID: 26548844
[TBL] [Abstract][Full Text] [Related]
15. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
[TBL] [Abstract][Full Text] [Related]
16. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
[TBL] [Abstract][Full Text] [Related]
17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
18. BK channels blockage inhibits hypoxia-induced migration and chemoresistance to cisplatin in human glioblastoma cells.
Rosa P; Catacuzzeno L; Sforna L; Mangino G; Carlomagno S; Mincione G; Petrozza V; Ragona G; Franciolini F; Calogero A
J Cell Physiol; 2018 Sep; 233(9):6866-6877. PubMed ID: 29319175
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-mediated cancer stem cells in pseudopalisades with activation of hypoxia-inducible factor-1α/Akt axis in glioblastoma.
Inukai M; Hara A; Yasui Y; Kumabe T; Matsumoto T; Saegusa M
Hum Pathol; 2015 Oct; 46(10):1496-505. PubMed ID: 26256949
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
